Residency · Residency · Infectiousdisease

Travel Medicine and Tropical Infections

Pre-Travel Consultation

Risk Assessment Framework

The pre-travel consultation requires a systematic assessment of risk that integrates multiple dimensions of the planned trip with the individual traveler's health profile. Key trip-related factors include the specific destination at the regional and local level, with particular attention to whether the itinerary includes rural versus urban areas, the duration of travel, the purpose of the trip (tourism versus visiting friends and relatives, the latter carrying substantially higher risk for diseases such as malaria), the type of accommodations, and planned activities such as adventure sports, freshwater exposure, or animal contact.

The traveler's health status is equally important and includes assessment of age, immunosuppressive conditions or medications, pregnancy status, and chronic diseases that may alter vaccine eligibility or increase susceptibility to travel-related infections. Itinerary-specific risks should be explored in detail, including plans for high-altitude travel, freshwater swimming or wading, exposure to animals, and potential for sexual contact during travel.

Routine and Travel-Specific Vaccinations

The pre-travel consultation should begin with verification that all routine vaccinations are up to date, including measles-mumps-rubella, tetanus-diphtheria-pertussis, varicella, influenza, COVID-19, and pneumococcal vaccines as age-appropriate. Travel-specific vaccinations are then recommended based on the itinerary and risk assessment.

Hepatitis A vaccination is recommended for all travelers to developing countries. The two-dose series, administered at zero and six to twelve months, provides long-term immunity, and a single dose provides protection within approximately two weeks of administration. Hepatitis B vaccination is a universal recommendation, and an accelerated schedule of doses at zero, seven, and twenty-one days with a booster at twelve months is available for travelers departing on short notice. Typhoid vaccination is indicated for travel to endemic areas of South Asia, Southeast Asia, and Africa, and is available as either the Ty21a oral live vaccine or the Vi polysaccharide intramuscular vaccine. Neither typhoid vaccine provides complete protection, and food and water precautions remain essential.

Yellow fever vaccination is required for entry to many African and South American countries. The vaccine is a live attenuated preparation that is now considered valid for life, replacing the previous ten-year validity. It is contraindicated in immunosuppressed individuals, infants younger than six months, and patients with thymus disorders. Japanese encephalitis vaccine (Ixiaro, an inactivated preparation) is recommended for travelers to rural Asia and is administered as a two-dose series. Rabies pre-exposure prophylaxis, now a two-dose series administered on days zero and seven, is recommended for travelers to endemic areas who plan prolonged stays, activities such as spelunking, or veterinary work. Pre-exposure vaccination simplifies post-exposure management substantially, as it eliminates the need for rabies immune globulin, which may be unavailable in resource-limited settings.

Meningococcal ACWY and B vaccines are indicated for travelers to the sub-Saharan African meningitis belt during the dry season and are a requirement for participation in the Hajj pilgrimage. Cholera vaccine (Vaxchora, an oral live preparation) should be considered for travelers to areas with active cholera outbreaks, providing approximately 80 percent efficacy for three months.

Malaria Chemoprophylaxis

Malaria chemoprophylaxis is essential for travelers to endemic areas and must be tailored to the drug resistance patterns of the destination. The few remaining chloroquine-sensitive areas include Central America west of the Panama Canal, Hispaniola, and limited parts of the Middle East. For these destinations, chloroquine 500 milligrams weekly, begun one to two weeks before travel and continued for four weeks after return, is appropriate.

For chloroquine-resistant areas, which encompass the vast majority of malaria-endemic regions including sub-Saharan Africa and South and Southeast Asia, three regimens are recommended. Atovaquone-proguanil (Malarone) is the best-tolerated option, started one to two days before travel, taken daily during the trip, and continued for only seven days after return, making it particularly suitable for short trips. Doxycycline 100 milligrams daily, started one to two days before travel and continued for four weeks after return, offers the additional advantage of providing coverage against rickettsial infections and leptospirosis. Mefloquine, taken weekly starting two to three weeks before travel and continuing four weeks after return, is effective but carries a risk of neuropsychiatric side effects including vivid dreams, anxiety, and rarely psychosis, and should be avoided in patients with a history of seizures or psychiatric disorders.

Standby emergency treatment is an additional strategy for travelers to remote areas where medical care may not be available within 24 hours. Self-treatment with artemether-lumefantrine is provided to the traveler with clear instructions for initiation if symptoms of malaria develop and prompt medical evaluation is not possible.

Travelers' Diarrhea Prevention and Treatment

Travelers' diarrhea is the most common travel-related illness, affecting 30 to 70 percent of travelers to developing regions. The most common bacterial cause is enterotoxigenic Escherichia coli, followed by Campylobacter, Salmonella, and Shigella. Norovirus is an important viral cause, and parasitic etiologies become more common during prolonged stays. Prevention relies primarily on food and water precautions, often summarized as "boil it, cook it, peel it, or forget it." Bismuth subsalicylate taken as two tablets four times daily provides approximately 60 percent prevention.

Treatment is stratified by severity. For mild disease that is tolerable and without fever or bloody stools, loperamide alone or bismuth subsalicylate is sufficient. For moderate disease that is distressing but not incapacitating, azithromycin as a 1,000 milligram single dose or 500 milligrams daily for three days is the preferred treatment, having supplanted fluoroquinolones as the first-line agent because of high rates of Campylobacter fluoroquinolone resistance, particularly in Southeast Asia. For severe disease characterized by incapacitating symptoms, fever, or bloody diarrhea, azithromycin 500 milligrams daily for three days is recommended. In regions outside Southeast Asia where fluoroquinolone resistance is less prevalent, ciprofloxacin 500 milligrams twice daily for three days remains an acceptable alternative. Rifaximin 200 milligrams three times daily for three days is an option for non-invasive, non-febrile diarrhea only, as this agent is not absorbed systemically and therefore has no efficacy against invasive pathogens.

<image>A world map infographic showing key travel medicine risks by geographic region. Show major regions with color-coded overlay: (1) Sub-Saharan Africa: malaria (chloroquine-resistant), yellow fever, meningitis belt, Ebola/Marburg zones. (2) South/Southeast Asia: malaria, dengue, typhoid, JE, Nipah. (3) Central/South America: malaria, dengue, Zika, yellow fever, Chagas, coccidioidomycosis. (4) Middle East: MERS, malaria (limited). (5) Caribbean: dengue, Zika, chikungunya. Include a legend showing icons for: required vaccines, recommended vaccines, malaria chemoprophylaxis needed, special precautions. Add a sidebar showing "Top 5 travel-related infections by frequency: travelers' diarrhea, respiratory infections, skin infections, febrile illness, malaria." Use a professional geographic information system (GIS) map style.</image>

Fever in the Returning Traveler

Approach

The evaluation of fever in a traveler returning from an endemic area requires a detailed and methodical approach. A comprehensive travel history must include exact destinations with dates, specific exposures including freshwater contact, insect exposure, animal contact, sexual contacts, and contact with healthcare facilities. This information, combined with knowledge of incubation periods, guides the differential diagnosis.

Short incubation periods of fewer than ten days suggest dengue, chikungunya, rickettsial diseases, bacterial enteric infections, and influenza. Medium incubation periods of ten to twenty-one days raise consideration of malaria, typhoid fever, leptospirosis, acute HIV infection, and acute schistosomiasis, also known as Katayama fever. Long incubation periods exceeding twenty-one days should prompt evaluation for malaria (recognizing that Plasmodium vivax and ovale can relapse months after exposure due to hepatic hypnozoites), tuberculosis, visceral leishmaniasis, amoebic liver abscess, viral hepatitis, and brucellosis.

Initial Workup

The initial laboratory evaluation of the febrile returning traveler should include a complete blood count with differential, basic metabolic panel, liver function tests, blood cultures, thick and thin malaria smears obtained three times at twelve to twenty-four hour intervals, a rapid malaria antigen test, urinalysis, and chest radiography. Additional serologic testing should be directed by exposure history and may include dengue NS1 antigen and IgM, Rickettsia serology, leptospirosis serology, and HIV testing. The finding of peripheral eosinophilia should prompt evaluation for helminthic infections, including schistosomiasis, strongyloides, hookworm, and filariasis.

Malaria

Life Cycle and Species

Understanding the five Plasmodium species pathogenic to humans is essential for appropriate diagnosis and treatment. Plasmodium falciparum is the most lethal species, capable of achieving the highest parasitemia due to its ability to invade red blood cells of all ages, and is the predominant species in sub-Saharan Africa. It does not produce hypnozoites and therefore does not relapse from hepatic stages after clearance of the blood-stage infection.

Plasmodium vivax is the most geographically widespread species and is characterized by its production of hypnozoites, dormant hepatic forms that can reactivate weeks to months after initial infection, causing clinical relapse. P. vivax preferentially infects Duffy-positive red blood cells, which explains its relative rarity in West Africa where Duffy negativity is prevalent. Plasmodium ovale, also capable of producing hypnozoites and therefore relapsing infection, is found primarily in West Africa. Plasmodium malariae causes quartan malaria with a 72-hour fever cycle and can persist at very low parasitemia levels for decades. Plasmodium knowlesi is a zoonotic species with a macaque monkey reservoir found in Southeast Asia, distinguished by its rapid 24-hour replication cycle that can lead to rapidly escalating parasitemia.

Diagnosis

The gold standard for malaria diagnosis remains microscopic examination of Giemsa-stained thick and thin blood smears. The thick smear provides higher sensitivity and is used for initial screening, while the thin smear allows species identification and quantification of parasitemia. Rapid diagnostic tests that detect histidine-rich protein 2 for P. falciparum and parasite lactate dehydrogenase for other species provide sensitivity approaching 95 percent for P. falciparum at parasitemia levels above 100 parasites per microliter. However, false-negative results can occur with hrp2 and hrp3 gene deletions, an emerging concern particularly in certain regions of Africa. PCR-based testing offers the highest sensitivity and is particularly valuable for species confirmation and detection of mixed infections.

Treatment

Treatment of uncomplicated Plasmodium falciparum malaria from chloroquine-resistant areas relies on artemisinin-based combination therapy. Artemether-lumefantrine (Coartem), administered as four tablets twice daily for three days with fatty food to enhance absorption, is the most widely used regimen. Atovaquone-proguanil is an alternative for uncomplicated disease.

Severe P. falciparum malaria, defined by high parasitemia, organ dysfunction, or clinical severity criteria, is a medical emergency requiring intravenous artesunate, which is the first-line agent and has replaced intravenous quinine and quinidine based on the AQUAMAT trial demonstrating superior survival. Artesunate is administered at 2.4 milligrams per kilogram at zero, twelve, and twenty-four hours, then daily. In the United States, IV artesunate is available through the CDC under an investigational new drug protocol. Treatment is transitioned to oral artemisinin-based combination therapy when parasitemia falls below 1 percent and the patient can tolerate oral medications. Exchange transfusion for parasitemia exceeding 10 percent, while historically performed, has become less commonly used and remains controversial.

Treatment of Plasmodium vivax and ovale requires both blood-stage treatment with chloroquine for three days and radical cure to eliminate hypnozoites with primaquine at 0.25 milligrams per kilogram per day for fourteen days. Glucose-6-phosphate dehydrogenase testing must be performed before administering primaquine, as it can precipitate severe hemolytic anemia in G6PD-deficient individuals. Tafenoquine, a single-dose alternative for radical cure, offers improved adherence but also requires G6PD testing.

Dengue

Dengue, transmitted by Aedes aegypti and Aedes albopictus mosquitoes, is the most common arboviral infection worldwide, found throughout tropical and subtropical regions. The clinical presentation includes the abrupt onset of high fever, severe headache, retro-orbital pain, myalgia, arthralgia (earning the historical name "breakbone fever"), maculopapular rash, and characteristic laboratory findings of leukopenia and thrombocytopenia.

Severe dengue, the most dangerous manifestation, is characterized by plasma leakage with hemoconcentration, pleural effusions, and ascites, hemorrhagic manifestations, and organ impairment. A critical and counterintuitive clinical feature is that severe dengue occurs at the time of defervescence, typically between days three and seven, rather than during the acute febrile period. This phenomenon relates to immune-mediated vascular permeability and makes close monitoring during this window essential.

Diagnosis relies on the NS1 antigen test, which is positive during days one through five of illness, IgM serology, which becomes positive from day five onward, and PCR. Treatment is exclusively supportive, with careful intravenous fluid management during the critical phase. NSAIDs and aspirin must be avoided due to their effects on platelet function and bleeding risk. No specific antiviral therapy exists. Dengue vaccines include Dengvaxia, which is restricted to seropositive individuals only, as administration to seronegative individuals paradoxically increases the risk of severe dengue, and TAK-003 (Qdenga), a broader-use vaccine approved in some countries.

Typhoid Fever

Typhoid fever is caused by Salmonella enterica serovar Typhi and is transmitted through the fecal-oral route, with South Asia (particularly the Indian subcontinent) and Africa having the highest incidence. The clinical presentation follows a characteristic pattern of stepwise rising fever over one to two weeks, accompanied by relative bradycardia, hepatosplenomegaly, rose spots (salmon-colored blanching macules on the trunk), and either constipation or diarrhea.

Diagnosis can be challenging. Blood culture sensitivity ranges from 40 to 80 percent, while bone marrow culture, though rarely performed, remains the gold standard with sensitivity of 80 to 95 percent. The Widal test is unreliable due to poor sensitivity and specificity and should not be used for clinical decision-making. Treatment consists of ceftriaxone 2 grams intravenously daily for 10 to 14 days, or azithromycin 1 gram on day one followed by 500 milligrams daily for 5 to 7 days for uncomplicated oral treatment. Fluoroquinolone resistance is increasing, particularly in isolates from South Asia. Extensively drug-resistant typhoid, reported particularly from Pakistan, demonstrates resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, fluoroquinolones, and ceftriaxone, leaving azithromycin and carbapenems as the remaining treatment options.

<image>A clinical timeline showing the progression of dengue fever. Create a horizontal timeline spanning Day 1 to Day 10 divided into three phases: "Febrile Phase (Day 1-3)" showing high fever, headache, myalgia, rash onset with NS1 antigen positivity. "Critical Phase (Day 3-7)" highlighted in red showing defervescence with risk of plasma leakage (hemoconcentration, ascites, pleural effusion), hemorrhage, and organ impairment; show a hematocrit curve rising and platelet count curve falling. "Recovery Phase (Day 7-10)" showing resolution with fluid reabsorption and platelet recovery. Include a diagnostic testing timeline below: "NS1 antigen positive Day 1-5," "IgM positive from Day 5+," "PCR positive Day 1-7." Add warning signs box: "Abdominal pain, persistent vomiting, mucosal bleeding, lethargy, hepatomegaly, rising hematocrit with falling platelets → SEVERE DENGUE." Use a clinical monitoring chart style.</image>

Other Key Tropical Infections

Leptospirosis

Leptospirosis is caused by the spirochete Leptospira interrogans and is acquired through exposure to water contaminated with the urine of infected animals, particularly rodents. The disease follows a biphasic course, with the bacteremic phase characterized by abrupt onset of fever, headache, myalgia, and the relatively specific finding of conjunctival suffusion (conjunctival injection without purulent discharge), followed by the immune phase, which may include aseptic meningitis and uveitis. Weil disease represents the severe form of leptospirosis and is characterized by jaundice, renal failure, and hemorrhage, carrying a mortality of 5 to 15 percent. Diagnosis relies on serology, with the microscopic agglutination test serving as the gold standard, and PCR for early detection. Treatment of mild disease consists of doxycycline 100 milligrams twice daily for seven days, while severe disease requires intravenous penicillin G or ceftriaxone.

Rickettsial Infections (see also Tick-Borne Lecture)

Rickettsial infections are important causes of fever in returning travelers from tropical and subtropical regions. Scrub typhus, caused by Orientia tsutsugamushi and transmitted by chigger mites in Southeast Asia, presents with fever, eschar at the site of the mite bite, and regional lymphadenopathy, and responds to doxycycline. Murine typhus, caused by Rickettsia typhi and transmitted by fleas, causes fever, headache, and rash, and also responds to doxycycline. Epidemic typhus, caused by Rickettsia prowazekii and transmitted by body lice in conditions of crowding and poor hygiene, is treated with doxycycline.

Chikungunya

Chikungunya virus, transmitted by Aedes mosquitoes, produces a distinctive clinical syndrome dominated by severe polyarthralgia and arthritis affecting symmetric small joints, which may persist for months after the acute infection. Differentiation from dengue is important: chikungunya produces more prominent joint involvement, while dengue carries greater hemorrhagic risk. There is no specific antiviral treatment for chikungunya; management is supportive with anti-inflammatory agents.

Key Clinical Pearls

• Malaria must be excluded in ANY febrile traveler returning from an endemic area -- thick and thin smears x3 (12-24 hours apart) AND rapid diagnostic test
• IV artesunate is the first-line treatment for severe P. falciparum malaria -- it has replaced IV quinine/quinidine and dramatically improves survival
• Primaquine (or tafenoquine) for P. vivax/ovale radical cure requires G6PD testing -- omitting this step risks severe hemolytic anemia
• Dengue becomes dangerous at DEFERVESCENCE (critical phase) -- this is counterintuitive; close monitoring during days 3-7 is essential
• Azithromycin has replaced fluoroquinolones as the preferred empiric treatment for travelers' diarrhea in Southeast Asia due to Campylobacter fluoroquinolone resistance
• Eosinophilia in a returning traveler strongly suggests helminthic infection -- consider schistosomiasis, strongyloides, filariasis
• Yellow fever vaccine is required for entry to many African and South American countries and is valid for life
• VFR (visiting friends and relatives) travelers are the highest-risk group for malaria because they often do not seek pre-travel advice or take chemoprophylaxis

References

1. CDC. CDC Yellow Book 2024: Health Information for International Travel. New York, NY: Oxford University Press; 2024.
2. Lalloo DG, Shingadia D, Bell DJ, et al. UK malaria treatment guidelines 2016. J Infect. 2016;72(6):635-649.
3. Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. J Travel Med. 2017;24(Suppl 1):S57-S74.
4. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med. 2012;366(15):1423-1432.
5. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria (AQUAMAT). Lancet. 2010;376(9753):1647-1657.

Read this lecture as Markdown